Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Overview
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Companies Involved in Therapeutics Development
Agenus Inc
Amgen Inc
Heat Biologics Inc
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Drug Profiles
G-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HS-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Panvotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GRP94 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitespen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Dormant Products
Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: Heat Biologics announces first patient dosed in the first phase 1 trial of HS-130
Aug 12, 2019: Heat Biologics announces FDA clearance of IND application to begin phase 1 trial of HS-130 in combition with Heat’s HS-110
Apr 02, 2019: Heat Biologics delivers poster presentation at the AACR Annual Meeting 2019
Jun 01, 2015: Updated Phase 2 Data of Prophage In Newly Diagnosed GBM Presented at ASCO
May 14, 2015: Agenus Announces Oral Presentation at ASCO Highlighting Improved Survival with Prophage Immunotherapy in Brain Cancer Compared to Historical Controls
Jul 01, 2014: Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Fil Data Alysis
Jan 21, 2014: Agenus’ Prophage Vaccine for Glioma Hailed As a ?Very Promising Therapy’ in an Editorial Published in the Jourl Neuro-Oncology
Dec 16, 2013: Positive Phase 2 Results from Agenus’ Brain Cancer Vaccine Published in Neuro-Oncology
Sep 17, 2013: Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed Patients
May 22, 2013: Agenus Announces Initiation Of Enrollment In NCI-sponsored Randomized Trial Of Prophage G-200 Vaccine With Avastin In Treatment Of Brain Tumors
May 01, 2013: Agenus Announces Presentation Of Prelimiry Data From Phase II Clinical Trial Of Brain Cancer Vaccine At AANS Meeting
Apr 10, 2013: Agenus Presents Brain Cancer Vaccine Results At 81st AANS Annual Scientific Meeting 2013
Aug 08, 2012: Agenus Announces Publication Of Key Data Showing Antitumor Activity Of Prophage Vaccine In Clinical Cancer Research
Apr 17, 2012: Agenus Presents New Phase II Data From Brain Cancer Study Of Prophage Vaccine At Plery Session Of AANS
Apr 17, 2012: NCI Group Selects HSPPC-96 Vaccine For Randomized Large-Scale Study With Bevacizumab For Recurrent Glioblastoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Agenus Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Heat Biologics Inc, H1 2020
Dormant Projects, H1 2020